Share Price | LifeMD, Inc. Stock Analysis & Recommendation

Q: What does LifeMD, Inc. do?

Overview: LifeMD, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 66 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 2 Million (Quarterly Results - Mar 2025) Market cap: USD 618.58 Million (Micro Cap)Key Metrics: Debt Equity: 6.65 Return on Equity: 436.41% Price to Book: -265.63Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Should I buy, sell or hold LifeMD, Inc.?

Based on the current analysis of LifeMD, Inc., it would be prudent to hold your position in the stock rather than buy or sell at this time. The company is facing challenges with a negative book value and weak long-term fundamental strength, highlighted by a significant decline in operating profit over the past five years. While there have been positive results in recent quarters, including a notable increase in net sales and operating profit, the overall growth remains concerning, especially with a negative EBIT to interest ratio indicating difficulties in servicing debt. Additionally, the stock is considered risky, trading at high valuations despite a lack of profit growth over the past year.On a positive note, the company has a strong institutional ownership at 53.14%, suggesting that more experienced investors are backing it. However, given the mixed signals and underlying weaknesses, holding your investment seems to be the most cautious approach for now.

Q: Is LifeMD, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for LifeMD, Inc. has changed from sideways to mildly bearish. The weekly MACD is bearish, while the monthly MACD is bullish, indicating mixed signals. The Bollinger Bands and KST are both mildly bearish on a weekly and monthly basis, and Dow Theory also reflects a mildly bearish stance. Daily moving averages show a mildly bullish trend. In terms of performance, LifeMD has outperformed the S&P 500 on a year-to-date basis with a return of 29.90% compared to the S&P 500's 12.22%, and over three years, it has significantly outperformed with a return of 179.57% against the S&P 500's 70.41%. Overall, the current technical stance is mildly bearish, with key indicators such as the weekly MACD and Bollinger Bands driving this view.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

339.68 k

Shareholding (Sep 2025)

FII

11.43%

Held by 50 FIIs

DII

68.72%

Held by 22 DIIs

Promoter

0.79%

How big is LifeMD, Inc.?

22-Jun-2025

As of Jun 18, LifeMD, Inc. has a market capitalization of 618.58 million and reported net sales of 234.00 million with a net profit of -10.17 million over the latest four quarters. Shareholder's funds are at -5.49 million, and total assets amount to 72.46 million.

View full answer

What does LifeMD, Inc. do?

22-Jun-2025

LifeMD, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $66 million and a net profit of $2 million. It has a market cap of $618.58 million and notable financial metrics, including a debt equity ratio of 6.65 and a return on equity of 436.41%.

View full answer

Should I buy, sell or hold LifeMD, Inc.?

22-Jun-2025

Is LifeMD, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, LifeMD, Inc. shows a mildly bearish technical trend despite strong year-to-date and three-year performance, with mixed signals from indicators like the weekly MACD and Bollinger Bands.

View full answer

Compare LifeMD, Inc. with Similar Stocks

CareMax, Inc.Talkspace, Inc.The Pennant Group, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate 11.30% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -23.04

The company has declared Positive results for the last 4 consecutive quarters

Risky - Negative Operating Profits

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 170 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-17.58

Return on Equity

-138.42%

Price to Book

129.65

Revenue and Profits:

Net Sales:

60 Million

(Quarterly Results - Sep 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-40.3%

6 Months

-51.91%

1 Year

-49.68%

2 Years

-47.49%

3 Years

45.37%

4 Years

-10.54%

5 Years

-85.81%

LifeMD, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

64.36%

EBIT Growth (5y)

11.30%

EBIT to Interest (avg)

-23.04

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

6.65

Sales to Capital Employed (avg)

27.08

Tax Ratio

4.12%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

65.42%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-248.81

EV to EBIT

-75.89

EV to EBITDA

215.33

EV to Capital Employed

-31.66

EV to Sales

2.41

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 32 Schemes (19.07%)

Foreign Institutions

Held by 50 Foreign Institutions (11.43%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -3.22% vs -5.33% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -125.00% vs -184.21% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "60.20",
          "val2": "62.20",
          "chgp": "-3.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.00",
          "val2": "1.90",
          "chgp": "-47.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.70",
          "chgp": "-57.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.60",
          "val2": "-1.60",
          "chgp": "-125.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-32.70%",
          "val2": "-14.60%",
          "chgp": "-1.81%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 39.34% vs 28.15% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -5.06% vs 60.44% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "212.50",
          "val2": "152.50",
          "chgp": "39.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.70",
          "val2": "-7.90",
          "chgp": "15.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.20",
          "val2": "2.60",
          "chgp": "-15.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.70",
          "val2": "-17.80",
          "chgp": "-5.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-76.00%",
          "val2": "-95.00%",
          "chgp": "1.90%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

60.20

62.20

-3.22%

Operating Profit (PBDIT) excl Other Income

1.00

1.90

-47.37%

Interest

0.30

0.70

-57.14%

Exceptional Items

-1.20

0.00

Consolidate Net Profit

-3.60

-1.60

-125.00%

Operating Profit Margin (Excl OI)

-32.70%

-14.60%

-1.81%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is -3.22% vs -5.33% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is -125.00% vs -184.21% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

212.50

152.50

39.34%

Operating Profit (PBDIT) excl Other Income

-6.70

-7.90

15.19%

Interest

2.20

2.60

-15.38%

Exceptional Items

0.00

-0.30

100.00%

Consolidate Net Profit

-18.70

-17.80

-5.06%

Operating Profit Margin (Excl OI)

-76.00%

-95.00%

1.90%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 39.34% vs 28.15% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -5.06% vs 60.44% in Dec 2023

All Annual Results

Company CV

About LifeMD, Inc.

LifeMD, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

LifeMD, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is LifeMD, Inc.?

Watch in Real-Time

What does LifeMD, Inc. do?

Should I buy, sell or hold LifeMD, Inc.?

Is LifeMD, Inc. technically bullish or bearish?

Compare LifeMD, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

The company has declared Positive results for the last 4 consecutive quarters

Risky - Negative Operating Profits

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About LifeMD, Inc.

Company Coordinates